In our study, importantly, these combined phenotypes were noted in patients affected by the neurodegenerative diseases caused by the SLC16A2, ARSA, FOXG1, or FH mutations (Figure 3), which warrants the monitoring of disease progression in the affected patients. This evidence concerns the gene ARSA and neurodegenerative disease.